YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada
- 34 minutes ago
- 3 min read
The six-month pilot is designed to evaluate the potential scalability of bringing physician-ordered, blood-based OkaiDx laboratory-developed tests to patients in Canada
Taipei, Taiwan, July 28, 2026 --- We are pleased to announce the launch of a six-month pilot collaboration (the "Pilot") with Numia Health Inc., a British Columbia–based healthcare services provider ("Numia Health"), pursuant to a Pilot Service Agreement dated July 23, 2026 (the "Agreement") among YD Bio, our subsidiary YD Bio US Inc. ("YD Bio US"), our affiliate EG BioMed US Inc. ("EG BioMed US"), and Numia Health. Together, we are establishing a cross-border clinical workflow designed to support physician-ordered, blood-based cancer testing for eligible patients in British Columbia, Canada.
Under the Agreement, we intend to evaluate an integrated clinical pathway that combines physician access, certified mobile blood collection, cross-border specimen logistics, and laboratory testing at our EG BioMed US CLIA-certified, CAP-accredited laboratory in Bothell, Washington (the "Laboratory"). The Pilot is initially limited to up to 50 patient episodes in the Lower Mainland region of British Columbia and is expected to support our OkaiDx blood-based laboratory-developed tests (LDTs) for breast, colorectal, pancreatic, liver, and gastrointestinal cancers. Numia Health will coordinate physician requisitions, mobile blood collection, specimen preparation, and logistics, with laboratory analysis to be primarily performed by EG BioMed US in the United States, and YD Bio US participating as our commercial partner.
This Pilot represents our first structured clinical-access initiative in Canada. It follows our July 2, 2026 announcement of the Laboratory's expansion of its U.S. footprint and reflects our broader strategy of building a cross-border molecular diagnostics platform through an asset-light, partnership-driven model that pairs our accredited U.S. laboratory with local physician and logistics networks. We designed this Pilot to evaluate the scalability of this cross-border clinical access model, and it may serve as a foundation for potential future expansion in the Canadian market.
"This collaboration reflects our strategy of expanding patient access to advanced molecular diagnostics through strong healthcare partnerships," said Dr. Ethan Shen, our Founder, Chairman and Chief Executive Officer. "Through this pilot, we aim to evaluate a scalable cross-border testing workflow that is designed to broaden access for patients while maintaining the laboratory quality and regulatory standards that underpin our platform."
We designed the Pilot to evaluate operational workflows, specimen logistics, and patient experience before we consider any broader, non-exclusive commercial collaboration, which would be subject to the successful completion of the Pilot and the execution of additional agreements. Our OkaiDx tests are laboratory-developed tests performed exclusively at our EG BioMed US Laboratory, solely at the request of a prescribing healthcare provider; they have not been cleared or approved as medical devices by the U.S. Food and Drug Administration or Health Canada and are offered in accordance with applicable requirements governing laboratory-developed tests.
About Numia Health
Numia Health is a Canadian healthcare company modernizing how patients access diagnostic testing. By combining an online physician-ordering platform with certified mobile blood collection, Numia Health eliminates waiting rooms and referral hurdles, empowering patients with preventative health data through fast, medical-grade lab testing paired with clear, actionable insights. For more information, please visit https://numiahealth.ca.
About EG BioMed US
EG BioMed US Inc. is our U.S. clinical-laboratory subsidiary of EG BioMed Co., Ltd., a Taiwan company and our affiliate. It operates a CLIA-certified, CAP-accredited clinical laboratory in Bothell, Washington, focused on DNA methylation–based early cancer detection.
About YD Bio Limited
YD Bio is a U.S.-anchored public biotechnology company building an integrated healthcare platform spanning regulated molecular diagnostics, clinical services, precision medicine, and life science commercialization. We operate DNA methylation–based oncology testing programs in the United States under a laboratory-developed test strategy and support pharmaceutical and biotechnology partners through compliant life science distribution and clinical trial supply chain services. In addition, we maintain regulated ocular health commercialization operations and a consumer health distribution platform in Asia. For more information, visit ir.ydesgroup.com and follow the Company on Facebook, X, Threads, Instagram and LinkedIn.
Forward-Looking Statements
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions created by the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance. Actual results may differ materially due to various factors described in our filings with the U.S. Securities and Exchange Commission (the "SEC"). We undertake no obligation to update any forward-looking statements, except as required by law.
For investor and media inquiries, please contact:
YD Bio Limited Investor Relations
Email: investor@ydesgroup.com
WFS Investor Relations Inc.
Phone: +1 628 283 9214
Selected Media Coverage
